SECURITIES AND EXCHANGE COMMISSION
                               WASHINGTON, D.C. 20549

                                   FORM 10-KSB
(Mark One)

(X)   ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
                                EXCHANGE ACT OF 1934

For the Fiscal Year Ended June 30, 2002
                                       OR
( )   TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
                                EXCHANGE ACT OF 1934

Commission File No. 0-29895

                               Royce Biomedical, Inc.
                        --------------------------------
                   (Name of Small Business Issuer in its charter)

                Nevada                                      98-0206542
         ----------------------                        --------------------
         (State of incorporation)                        (IRS Employer
                                                       Identification No.)
      1100-1200 West 73rd Avenue
       Vancouver, British Columbia                            V6P 6G5
----------------------------------------------------  ------------------------
   (Address of Principal Executive Office)                     Zip Code

Registrant's telephone number, including Area Code: (604)-267-7080 Securities
registered pursuant to Section 12(b) of the Act: None Securities registered
pursuant to Section 12(g) of the Act:

                                  Common Stock
                                (Title of Class)

Check whether the Registrant (1) has filed all reports required to be filed by
Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12
months (or for such shorter period that the Registrant was required to file such
reports) and (2) has been subject to such filing requirements for the past 90
days.
                                  X
                                 ----              ----
                                  YES               NO

Check if disclosure  of delinquent  filers in response to Item 405 of Regulation
S-B is not contained in this form, and no disclosure  will be contained,  to the
best  of  the  Registrant's   knowledge,  in  definitive  proxy  or  information
statements  incorporated  by  reference  in Part III of this Form  10-KSB or any
amendment to this Form 10-KSB. [X]

The Company's revenues during the year ended June 30, 2002 were $-0-.

The aggregate market value of the voting stock held by non-affiliates of the
Company (2,929,461 shares) based upon the closing priceaverage bid and asked
prices of the Company's common stock on September 30, 2002 was approximately
60,000.

Documents incorporated by reference:      None

As of September 30, 2002 the Company had 5,051,683 issued and outstanding shares
of common stock.


<PAGE>


ITEM 1.  DESCRIPTION OF BUSINESS

     Royce  Biomedical,  Inc. (the  "Company") was  incorporated in the State of
Nevada on March 22, l995.

      Royce Biomedical, Inc. (the "Company") was incorporated in Nevada on March
22, l995. The Company is a public company listed on the OTC Bulletin Board. The
trading symbol is RYBO.OB. The Company's executive offices are located at
1100-1200 West 73rd Avenue, Vancouver, British Columbia, V6P 6G5 CANADA. The
Company's telephone number is (604) 267-7080 and its facsimile number (604)
267-7078. The Company has a Sales Office in Beijing, the People's Republic of
China.

Introduction

      Health care around the world is divided into two segments, diagnosis and
treatment. This segmentation has given rise to two separate markets: the
pharmaceutical market for treatment and the medical diagnostic testing devices
market for diagnosis. The market demand for rapid tests is huge. It is reported
that 36 million people around the world are infected with AIDS virous. Sexually
transmitted diseases such as Syphilis and HBV are on the rise. Although not as
life threatening, early detection of non-sexually trasmitted dieseases such as
H. Pylori can reduce the development risk of cancer.

      The Company is a developer, manufacturer and distributor of
immunodiagonsitic test products. The Company plans to manufacture and assemble
diagnostic test kits in China.

Corporate Development

      Between August 1995 and June 1998, the Company manufactured and sold
diagnostic test kits used to detect pregnancy, thyroid disorders and other
medical conditions. It has since upgraded its research ability and expanded into
tests for HIV and H. Pylori and Syphilis. Between 1996 and 1998 the Company
assembled its diagnostic testing kits at its laboratory in Irvine, California.
To streamline its operation, the Company closed this facility in April 1998.

      In January, 2001, the Company registered a Sales Office in Beijing, the
People's Republic of China. By registering this Sales Office in the Zhong Guan
Cun Hi-Tech Development Zone, the Company can benefit from tax concessions
granted by the Chinese government.

      At the present time the Company plans to manufacture its own medical
diagnostic tests in China. This will enable the Company to reduce operating
costs and make its products more competitive.

      The Company intends to begin manufacturing and distributing HIV, H.Pylori
and Syphilis test kits in China in December 2002.


<PAGE>


      In order to penetrate the Chinese immunodiagonstic market quickly, the
Company signed an agreement in April 1999 with Xili Pharmaceutical Group, Inc.
("Xili") of the People's Republic of China to market and distribute H. Pylori
diagnostic test kits supplied by the Company. In addition to supplying H. Pylori
test kits to Xili, the Company provides clinical data and in-person training to
Xili personnel. Similar arrangements have been established between the Company
and Xili to market HIV and Syphilis tests.

      Xili Pharmaceutical Group, Inc. is a major shareholder of the Company.
Xili has a large sales force in China that services the medical purchasing needs
of clinics, laboratories, hospitals, and consumers. Operating in more than 60
cities, Xili has strong working relationships with over 2000 hospitals in China.
It also has close working relationship with the Chinese Medical Association,
several of the largest drug store chains and a number of test kit distributors
in China. Xili is controlled by Dr. Yan Xiao Wen, who is also the Chairman of
the Company's Board of Directors.

      In April 2001 the Company signed an agreement with Osborn Scientific Group
(OSG), an immunodiagonstic test research laboratory in the United States, to
develop new products for the Company.

The Company's Current Postion in China

      The Company has spent the last two years developing a distribution network
and working with the Chinese regulatory authorities to obtain the necessary
approvals for various products. The Company has been granted licenses to sell H.
Pylori and Tuberculosis test kits. The Company is currently holding discussions
with Chinese regulatory authorities to obtain approval to distribute HIV and
Syphilis test kits.

Potential Market for the Company Products

      The Company, through its own research, has identified H. Pylori, HIV,
Tuberculosis and Syphilis as the initial diagnostic test kits which it plans to
manufacture and distribute in China. The following is a summery of each market.

      Non Sexually Transmitted Diseases - Reports indicate that H. Pylori has
infected over 780 million people in China. H. Pylori infection is the main cause
of chronic gastritis (60% detectable rate in China), chronic active gastritis
(over 90%), duodenal ulcer (95%), and gastric ulcer (80%). Studies show that
H.Pylori is a major cause for stomach cancer. The early treatment of H. Pylori
infection can reduce the need for invasive endoscopy and long-term traditional
therapy associated with duodenal and gastric ulcers, as well as antral
gastritis. H. Pylori is an easily curable illness, but early detection is vital
for treatment since the symptoms at early stages are not very obvious.

      In November 1999 Xili began distributing 20,000 H. Pylori test kits
supplied by the Company to 100 hospitals in China as samples. The initial
results were very satisfactory and encouraging. The Company will enlarge the
sampling hospitals to 500 in 2002 and start to sell the test kits to the first
100 hospitals. The Company's goal is to sell at least 1000 test kits to each


<PAGE>

hospital during 2002. The Company expects to receive approximately $2.00 from
the sale of each H. Pylori testing kit. The Company expects to capture 20% of H.
Pylori test kit market by 2004.

      Sexually Transmitted Dieseases - AIDS has been identified by the Chinese
government as a major threat to the public health in China. According to
official statistics, over 850,000 people are HIV positive. This number is
estimated to grow by 30% annually. The Chinese government is taking measures to
prevent AIDS from becoming an epidemic.

      The Chinese government requests mandatory tests for all marrying couples.
HIV, HBV and Syphilis tests result are usually required before issuing a
marriage certificate. It estimated that over 9 million couples are married each
year in China.

      Currently, tests for HIV, HBV and Syphilis are performed separately. Not
only is it time consuming, but also costly for both the government and
individuals. The Company has applied for a patent covering a single diagnostic
test kit which will detect HIV, HBV and Syphilis.

      In addition, there are approximately 50,000 blood stations and blood banks
that can also use the Company's test kits.

      If successful in the Chinese market, the Company may explore marketing and
sales opportunities in other countries.

      All of the Company's sales have been to customers outside of the United
States. For the foreseeable future, the Company does not plan to sell any of its
products in the United States.

Competition

    There are competitors presently operating in China but comparative tests
conducted by National Institute of Virology and the State Protection Medical
Institute of China have shown the Company's products to be superior. The field
in which the Company operates is subject to rapid technological change and there
can be no assurance that the Company will be able to react and adapt to any such
changes or that developments by competitors will not cause the products
distributed by the Company to be obsolete.

Regulation

      Foreign Regulations. The Company has licenses from the State Drug
Authority of the People's Republic of China for the import and distribution of
H. Pylori and M. Tuberculosis (TB) test kits in China. The Company will attempt
to acquire the rights and licenses necessary to distribute other diagnostic test
kits in China. Although the process to secure a license is relatively expensive
and time consuming, the Company believes that having Xili as a partner in China
will assist the Company in future dealings with Chinese regulatory agencies.
There is no assurance however that the Company will be successful in obtaining
licenses for the sale of additional diagnostic testing kits in China.


<PAGE>

      In order to sell outside the United States, medical devices, manufactured
in the United States, including diagnostic testing kits, are subject to FDA
permit requirements that are conditioned on clearance by the importing country's
appropriate regulatory authorities. Many countries further require imported
medical devices to comply with their own or international standards. Although
the Company believes its products can be produced in compliance with the
regulations, no assurance can be given that the Company's products will continue
to meet standard, which may be established from time to time by the Chinese or
other foreign government.

      Regulation in the People's Republic of China The sale of medical devices
are regulated by the State Drug Authority of the People's Republic of China
(SDA). SDA exercises significant regulatory control over the manufacture of
medical devices.

      Before a medical device can be marketed in China, approval of the SDA must
be obtained. In the case of SDA, testing programs are typically required in
order to establish product safety and efficacy.

      SDA regulations pertain not only to medical devices, but also to the
processes and facilities used to manufacture such products. Among the conditions
for marketing products cleared by the SDA is the requirement that the
prospective manufacturer's quality control and manufacturing procedures conform
to the SDA's Good Manufacturing Practice ("GMP") regulations, which must be
followed at all times. In complying with standards set forth in these
regulations, manufacturers must continue to expend time, money and effort in the
areas of production and quality control to ensure full technical compliance. GMP
regulations require adherence to strict quality control procedures, including
documentation of all aspects of the manufacturing process, to demonstrate that
products are made by a "controlled" process that ensures consistency and
reliability of the end product. Significant changes to the manufacturing process
require notification to the SDA, and all changes require documentation. The SDA
has the right to conduct inspections of the manufacturing facility at any time
at its discretion. To the extent all or a portion of the manufacturing process
for a product is handled by an entity other than the Company, the Company must
similarly receive SDA approval for the other entity's participation in the
manufacturing process. Manufacturing establishments in China are subject to
inspections by the SDA and by other government agencies and must comply with
"GMP" as appropriate for production. In complying with GMP regulations,
manufacturers must continue to expend time, money and effort in the area of
production and quality control to ensure full technical compliance.

Stock Splits

      All information in this registration statement has been adjusted to
reflect a five-for-one reverse split of the Company's common stock which was
effective May 11, 1998 and a three-for-one reverse split of the Company's common
stock which was effective May 30, 1999.



<PAGE>


Employees

      As of September 30, 2002, the Company did not have any full-time
employees. The Company plans to hire employees as may be required by the level
of the Company's operations.


ITEM  2. DESCRIPTION OF PROPERTY

     See Item 1 of this report.

ITEM 3.  LEGAL PROCEEDINGS.
--------------------------

      The Company is not engaged in any litigation, and the officers and
directors presently know of no threatened or pending litigation in which it is
contemplated that the Company will be made a party.

ITEM 4.  SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.
-------------------------------------------------------------

         Not Applicable

ITEM 5.  MARKET PRICE OF AND DIVIDENDS ON THE REGISTRANT'S COMMON EQUITY AND
--------------------------------------------------------------------------------
OTHER SHAREHOLDER MATTERS.
-------------------------

      As of September 30, 2002, there were approximately 365 record owners of
the Company's Common Stock. The Company's Common Stock is traded on the National
Association of Securities Dealers OTC Bulletin Board under the symbol "RYBO".
Set forth below are the range of high and low bid quotations for the periods
indicated as reported by the NASD. The market quotations reflect interdealer
prices, without retail mark-up, mark-down or commissions and may not necessarily
represent actual transactions.

      The share prices shown in the table have been adjusted to reflect a
five-one reverse stock effective May 11, 1998 and a three-for-one reverse stock
split effective May 30, 1999.


            Quarter Ending              High           Low

                9/30/99                 $0.12          $0.10
               12/31/99                 $0.18          $0.06
                3/31/00                 $0.12          $0.06
                6/30/00                 $0.44          $0.06

                9/30/00                 $0.25          $0.18
               12/31/00                 $0.15          $0.06
                3/31/01                 $0.18          $0.06
                6/30/01                 $0.14          $0.04


<PAGE>

                9/30/01                 $0.04          $0.04
               12/31/01                 $0.04          $0.02
                3/31/02                 $0.03          $0.02
                6/30/02                 $0.03          $0.02

      Holders of Common Stock are entitled to receive such dividends as may be
declared by the Board of Directors out of funds legally available therefor and,
in the event of liquidation, to share pro rata in any distribution of the
Company's assets after payment of liabilities. The Board of Directors is not
obligated to declare a dividend. The Company has not paid any dividends and the
Company does not have any current plans to pay any dividends.

ITEM 6.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND PLAN OF
         OPERATION

      At the present time the Company plans to assemble medical diagnostic test
kits in China to reduce costs. The Company plans to purchase the main components
for its test kits from manufacturers in the United States. In this regard Osborn
Scientific Group has indicated its willingness to sell to the Company components
that would allow the assembly of H. Pylori and other diagnostic kits in China.
Xili has agreed to supply the required assembly space in one of its
pharmaceutical manufacturing plants.

    The Company may also attempt to obtain the necessary approvals to
manufacture the components of the H. Pylori and other test kits in China. Rather
than building its own manufacturing facility, the Company would pursue the
acquisition of a subsidiary of Xili that manufactures pharmaceutical products.

    During the year ended June 30, 2002 the Company had a net loss of
$(105,500). The Company satisfied its cash needs during this period through
increases in accounts payables and accrued liabilities and cash on had at the
beginning of the year.

    During the year ended June 30, 2001 the Company had a net loss of
$(134,939). During this same period the Company's operations used $378,478 in
cash. The Company satisfied its cash needs during this period through the sale
of common stock and cash on hand at the beginning of the year.

    The Company does not have any available credit, bank financing or other
external sources of liquidity. Due to historical operating losses, the Company's
operations have not been a source of liquidity. In order to obtain capital, the
Company may need to sell additional shares of its common stock or borrow funds
from private lenders. During the twelve months ending June 30, 2003 the Company
will need approximately $5,000,000 in additional capital for acquisition of a
subsidiary of Xili that manufactures pharmaceutical products and manufacturing
H. Pylori test kits in China. In addition, if during the year ending June 30,
2003, the Company suffers additional losses, the Company will need to obtain
additional capital in order to continue operations.


<PAGE>

ITEM 7.  FINANCIAL STATEMENTS

      See the financial statements attached to this report.

ITEM 8.  CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS.
------------------------------------------------------

      None.

ITEM 9. DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS AND CONTROL PERSONS

      The following sets forth certain information concerning the present
management of the Company:

         Name                 Age         Position with Company

         Dr. Yan Xiao Wen     43          Chairman of the Board of Directors
         Kathy Jiang          44          President and a Director
         Helen Zhao           37          Secretary and a Director

     Dr. Yan Xiao Wen has been a director of the Company  since April 1999.  Dr.
Yan has been the President of Xili  Pharmaceutical  (Group) Inc., (Xili Beijing,
Xili Hebei, Xili Zaozhuang, Xili Hezhe, Xili Chongqing, Xili Hubai) and Xili USA
Inc. since December 1993.

     Kathy Jiang has been the  President  and a director  of the  Company  since
April 1999.  Ms. Jiang was the Vice  President of Shandong  Canada  Trading from
March 1993 to November 1998.

     Helen Zhao has been the Company's  Secretary and a director since 2001. For
the past eight years Ms. Zhao has the controller for Richmond Motor Sports.  For
the past three years Ms. Zhao has also been the controller  for  Builddirect.com
Technology Inc.

Consultant

     Dr.  Robert  Bohannon  is an  expert  in the  field of  immunoreagents  and
diagnostics  and  provides  consulting  services to the  Company.  Dr.  Bohannon
identifies leading diagnostic test kits through  independent  clinical analysis.
Dr. Bohannon also provides training to Xili's marketing and sales force.

ITEM 10.  EXECUTIVE COMPENSATION

      The following table sets forth in summary form the compensation received
by (i) the Chief Executive Officer of the Company and (ii) by each other
executive officer of the Company who received in excess of $100,000 during the
three fiscal years ended June 30, 2002.



<PAGE>


                      Annual Compensation              Long Term Compensation
                 ---------------------------------  ----------------------------

                                                     Re-                  All
                                          Other     stric-               Other
                                          Annual     ted                  Com-
Name and                                  Compen-   Stock    Options     pensa-
Principal        Fiscal  Salary  Bonus    sation    Awards   Granted     tion
Position          Year    (1)     (2)       (3)       (4)      (5)        (6)
---------        ------  ------  -----    ------    ------   -------    -------

Kathy Jiang,      2002  $30,200    --        --        --       --          --
President and     2001  $34,803    --        --        --  100,000          --
Chief Executive   2000  $33,931    --        --        --       --          --
Officer since
 April 1999

(1) The dollar value of base salary (cash and non-cash) received.

(2) The dollar value of bonus (cash and non-cash) received.

(3) Any other annual compensation not properly categorized as salary or bonus,
including perquisites and other personal benefits, securities or property.
Amount in the table represents automobile allowances.

(4) During the period covered by the foregoing table, the shares of restricted
stock issued as compensation for services. The table below shows the number of
shares of the Company's common stock owned by the officers listed above, and the
value of such shares as of June 30, 2002.

         Name                       Shares            Value

         Kathy Jiang              100,0000           $2,000


(5) The shares of common stock to be received upon the exercise of all stock
    options granted during the period covered by the table.

(6) All other compensation received that the Company could not properly report
    in any other column of the table including annual Company contributions or
    other allocations to vested and unvested defined contribution plans, and the
    dollar value of any insurance premiums paid by, or on behalf of, the Company
    with respect to term life insurance for the benefit of the named executive
    officer, and the full dollar value of the remainder of the premiums paid by,
    or on behalf of, the Company.

      The following shows the amounts which the Company expects to pay its
officers during the year ending June 30, 2003 and the time which the Company's
executive officers plan to devote to the Company's business. The Company does
not have employment agreements with any of its officers.
Options Granted During Fiscal Year Ending June 30, 2002

<PAGE>

      The Company did not grant any options to any officer or director during
the year ended June 30, 2002. As of June 30, 2002 none of the Company's officers
or directors held any options.

Long Term Incentive Plans - Awards in Last Fiscal Year

      None.

Employee Pension, Profit Sharing or Other Retirement Plans

      The Company does not have a defined benefit, pension plan, profit sharing
or other retirement plan, although the Company may adopt one or more of such
plans in the future.

Compensation of Directors

      Standard Arrangements. At present the Company does not pay its directors
for attending meetings of the Board of Directors, although the Company expects
to adopt a director compensation policy in the future. The Company has no
standard arrangement pursuant to which directors of the Company are compensated
for any services provided as a director or for committee participation or
special assignments.

      Other Arrangements. During the year ended June 30, 2002, and except as
disclosed elsewhere in this registration statement, no director of the Company
received any form of compensation from the Company.

      See " Stock Option and Bonus Plans" below for information concerning stock
options and stock bonuses granted to the Company's officers and directors.

Stock Option and Bonus Plans

      The Company has an Incentive Stock Option Plan, a Non-Qualified Stock
Option Plan and a Stock Bonus Plan. A summary description of each Plan follows.
In some cases these three Plans are collectively referred to as the "Plans".

      Incentive Stock Option Plan. The Incentive Stock Option Plan authorizes
the issuance of options to purchase up to 300,000 shares of the Company's Common
Stock, less the number of shares already optioned under both this Plan and the
Non-Qualified Stock Option Plan. The Incentive Stock Option Plan became
effective on September 15, 1999 and will remain in effect until September 15,
2009 unless terminated earlier by action of the Board. Only officers, directors
and key employees of the Company may be granted options pursuant to the
Incentive Stock Option Plan.

      In order to qualify for incentive stock option treatment under the
Internal Revenue Code, the following requirements must be complied with:

<PAGE>


        1. Options granted pursuant to the Plan must be exercised no later than:

         (a) The expiration of thirty (30) days after the date on which an
option holder's employment by the Company is terminated.

         (b) The expiration of one year after the date on which an option
holder's employment by the Company is terminated, if such termination is due to
the Employee's disability or death.

         2. In the event of an option holder's death while in the employ of the
Company, his legatees or distributees may exercise (prior to the option's
expiration) the option as to any of the shares not previously exercised.

         3. The total fair market value of the shares of Common Stock
(determined at the time of the grant of the option) for which any employee may
be granted options which are first exercisable in any calendar year may not
exceed $100,000.

         4. Options may not be exercised until one year following the date of
grant. Options granted to an employee then owning more than 10% of the Common
Stock of the Company may not be exercisable by its terms after five years from
the date of grant.

         5. The purchase price per share of Common Stock purchasable under an
option is determined by the Committee but cannot be less than the fair market
value of the Common Stock on the date of the grant of the option (or 110% of the
fair market value in the case of a person owning the Company's stock which
represents more than 10% of the total combined voting power of all classes of
stock).

      Non-Qualified Stock Option Plan. The Non-Qualified Stock Option Plan
authorizes the issuance of options to purchase up to 300,000 shares of the
Company's Common Stock less the number of shares already optioned under both
this Plan and the Incentive Stock Option Plan. The Non-Qualified Stock Option
Plan became effective on September 9, 1997 and will remain in effect until
September 9, 2007 unless terminated earlier by the Board of Directors. The
Company's employees, directors, officers, consultants and advisors are eligible
to be granted options pursuant to the Plan, provided however that bona fide
services must be rendered by such consultants or advisors and such services must
not be in connection with the offer or sale of securities in a capital-raising
transaction. The option exercise price is determined by the Committee but cannot
be less than the market price of the Company's Common Stock on the date the
option is granted.

      Options granted pursuant to the Plan not previously exercised terminate
upon the date specified when the option was granted.

      Stock Bonus Plan. Up to 100,000 shares of Common Stock may be granted
under the Stock Bonus Plan. Such shares may consist, in whole or in part, of
authorized but unissued shares, or treasury shares. Under the Stock Bonus Plan,

<PAGE>

the Company's employees, directors, officers, consultants and advisors are
eligible to receive a grant of the Company's shares; provided, however, that
bona fide services must be rendered by consultants or advisors and such services
must not be in connection with the offer or sale of securities in a
capital-raising transaction.

      Other Information Regarding the Plans. The Plans are administered by the
Company's Board of Directors. The Board of Directors has the authority to
interpret the provisions of the Plans and supervise the administration of the
Plans. In addition, the Board of Directors is empowered to select those persons
to whom shares or options are to be granted, to determine the number of shares
subject to each grant of a stock bonus or an option and to determine when, and
upon what conditions, shares or options granted under the Plans will vest or
otherwise be subject to forfeiture and cancellation.

      In the discretion of the Board of Directors, any option granted pursuant
to the Plans may include installment exercise terms such that the option becomes
fully exercisable in a series of cumulating portions. The Board of Directors may
also accelerate the date upon which any option (or any part of any options) is
first exercisable. Any shares issued pursuant to the Stock Bonus Plan and any
options granted pursuant to the Incentive Stock Option Plan or the Non-Qualified
Stock Option Plan will be forfeited if the "vesting" schedule established by the
Board of Directors at the time of the grant is not met. For this purpose,
vesting means the period during which the employee must remain an employee of
the Company or the period of time a non-employee must provide services to the
Company. At the time an employee ceases working for the Company (or at the time
a non-employee ceases to perform services for the Company), any shares or
options not fully vested will be forfeited and cancelled. In the discretion of
the Board of Directors payment for the shares of Common Stock underlying options
may be paid through the delivery of shares of the Company's Common Stock having
an aggregate fair market value equal to the option price, provided such shares
have been owned by the option holder for at least one year prior to such
exercise. A combination of cash and shares of Common Stock may also be permitted
at the discretion of the Board of Directors.

      Options are generally non-transferable except upon death of the option
holder. Shares issued pursuant to the Stock Bonus Plan will generally not be
transferable until the person receiving the shares satisfies the vesting
requirements imposed by the Board of Directors when the shares were issued.

      The Board of Directors of the Company may at any time, and from time to
time, amend, terminate, or suspend one or more of the Plans in any manner it
deems appropriate, provided that such amendment, termination or suspension
cannot adversely affect rights or obligations with respect to shares or options
previously granted. The Board of Directors may not, without shareholder
approval: make any amendment which would materially modify the eligibility
requirements for the Plans; increase or decrease the total number of shares of
Common Stock which may be issued pursuant to the Plans except in the case of a
reclassification of the Company's capital stock or a consolidation or merger of
the Company; reduce the minimum option price per share; extend the period for
granting options; or materially increase in any other way the benefits accruing
to employees who are eligible to participate in the Plans.

<PAGE>


      The Plans are not qualified under Section 401(a) of the Internal Revenue
Code, nor are they subject to any provisions of the Employee Retirement Income
Security Act of 1974.

      Summary. The following sets forth certain information as of September 30,
2002, concerning the stock options and stock bonuses granted by the Company.
Each option represents the right to purchase one share of the Company's Common
Stock.

                             Total        Shares                    Remaining
                             Shares    Reserved for       Shares     Options/
                            Reserved   Outstanding     Issued As     Shares
Name of Plan               Under Plan    Options      Stock Bonus   Under Plan
------------               ----------  ------------   -----------   ----------

Incentive Stock Option Plan  300,000         --            N/A       300,000
Non-Qualified Stock Option
  Plan                       300,000         --            N/A       300,000
Stock Bonus Plans            150,000        N/A             --       150,000


ITEM 11.  SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT.
-------------------------------------------------------------------------

     The following  table sets forth the number of and percentage of outstanding
shares of common  stock owned by the  Company's  officers,  directors  and those
shareholders  owning more than 5% of the Company's  common stock as of September
30, 2002.

                                   Shares of
Name and Address                  Common Stock          Percent of Class
----------------                  -------------       --------------------

Dr. Yan Xiao Wen                  2,022,222 (1)               40%
#205 - 1057 S.E. 17th Street
Fort Lauderdale, FL 33316, USA.

Kathy Jiang                         100,000                    2%
7531 Francis Rd.
Richmond, B.C. Canada V6Y 1A1

Helen Zhao                               --                    --
1100-1200 West 73rd Ave.
Vancouver, B.C. Canada V6P 6G5

Quantrum Assets Limited           1,500,000                   30%
3F, No. 68-8, Tien-Mou N. Road
Taipei, Taiwan, R.O.C.

<PAGE>


All Executive officers and        2,122,222                   42%
 directors as as a group
 (3 persons).

(1)  Represents  shares held by Xili USA, Inc., a corporation  controlled by Dr.
     Yan Xiao Wen.

ITEM 12.  CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS.

      The following table provides information concerning shares of the
Company's common stock issued to the Company's present and former officers,
directors and certain other third parties since the inception of the Company:

Date           Shares     Shareholder                      Consideration
----           ------     ----------------------------     -------------------

03-25-95     133,333      Ken Pappas                       $  2,000
08-15-97       6,666      Ken Pappas                       Services Rendered
01-20-98      33,333      Knight & Day Restaurant Corp.    $125,000
09-21-98     100,000      Knight & Day Restaurant Corp.    $ 45,000
01-19-99      92,222      Gregory Sharpe                   Services Rendered
04-12-99   2,222,222      Xili USA, Inc.                   $300,000
10-10-00     187,545      Knight & Day Restaurant Corp.    Payment of debt in
                                                           the amount of $37,509
01-31-01   1,500,000      Quantrum Assets Limited          $300,000

      In September 1997 Ken Pappas returned 33,333 shares of common stock to the
Company. These shares were cancelled and Mr. Pappas did not receive any
consideration for the return of these shares.

      Ken Pappas, is a director of Knight & Day Restaurant Corp. During the year
ended June 30, 2001, the Company loaned $83,540 to Ken Pappas. The loan was made
to permit Mr. Pappas to settle a lawsuit brought by a third party against the
Company and Mr. Pappas. The loan was due on April 9, 2002 and since June 9, 2001
has borne interest at a rate of 7.5% per year.

      Greg Sharpe and Ken Pappas resigned as officers and/or directors of the
Company during the year ended June 30, 2002.

      In January 2000 Xili USA, Inc. transferred 100,000 shares of common stock
to Kathy Jiang, an officer and director of the Company, and 100,000 shares of
common stock to an unrelated third party.

     Xili USA,  Inc.  is  controlled  by Dr.  Yan Xiao Wen,  a  director  of the
Company.



<PAGE>



                              ROYCE BIOMEDICAL INC.

                                  Vancouver, BC

                              FINANCIAL STATEMENTS

                        For the Year Ended June 30, 2002



<PAGE>


                              ROYCE BIOMEDICAL INC.
                          INDEX TO FINANCIAL STATEMENTS



Auditors' Report
Balance Sheet                                                     Exhibit "A"
Statement of Loss and Deficit                                     Exhibit "B"
Statement of Changes in Shareholders' Deficiency                  Exhibit "C"
Statement of Cash Flows                                           Exhibit "D"
Notes to Financial Statements                                     Exhibit "E"



                       -------------------------------


<PAGE>


                                AUDITORS' REPORT

 To the Shareholders of Royce Biomedical Inc.:

      We have audited the balance sheets of Royce Biomedical Inc. as at June 30,
2002 and 2001 and the statements of loss and deficit, changes in shareholders'
deficiency and cash flows for the years then ended. These financial statements
are the responsibility of the Company's management. Our responsibility is to
express an opinion on these financial statements based on our audits.

      We conducted our audit in accordance with generally accepted auditing
standards. Those standards require that we plan and perform an audit to obtain
reasonable assurance whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.

      In our opinion, these financial statements present fairly, in all material
respects, the financial position of the Company as at June 30, 2002 and 2001 and
the results of its operations and its cash flows for the years then ended in
accordance with generally accepted accounting principles applied on a basis
consistent with the prior year.


                                          "Cinnamon Jang Willoughby & Company"

                                          Chartered Accountants
Burnaby, BC
September 23, 2002

Comments by Auditor for US Readers on Canada-US Reporting Difference

      In the United States, reporting standards for auditors require the
addition of an explanatory paragraph when the financial statements are affected
by conditions and events that cast substantial doubt on the Company's ability to
continue as a going concern, such as those described in Note 6 to the financial
statements. Our report to the shareholders dated September 23, 2002 is expressed
in accordance with Canadian reporting standards which do not permit a reference
to such events and conditions in the auditors= report when these are adequately
disclosed in the financial statements.


                                          "Cinnamon Jang Willoughby & Company"

                                          Chartered Accountants
Burnaby, BC
September 23, 2002


<PAGE>

                                                                   Exhibit "A"
                              ROYCE BIOMEDICAL INC.
                                  Balance Sheet
                                  June 30, 2002
                                  (US Dollars)


Assets                                                     2002          2001

Current:
   Cash                                                 $    100      $  59,177
   Accounts receivable                                     8,600          7,519
Prepaid expenses and deposits                                  -        100,518
   Loan receivable - Director                                  -         82,894
                                                         ----------------------
                                                           8,700        250,108
Product license fees (Note 4)                            100,000              -
                                                         ----------------------
                                                        $108,700      $ 250,108


Liability
--------------------------------------------------------------------------------
Current:
   Accounts payable and accrued liabilities             $ 37,600      $  73,532


Shareholders' Equity

Share Capital (Note 5)                                    16,000         15,983
Contributed Surplus (Note 5)                           2,657,800      2,657,827
Deficit, per Exhibit "B"                               2,602,700      2,497,234
                                                          71,100        176,576


Going Concern (Note 6)
Commitments (Note 7)
                                                       $ 108,700      $ 250,108





<PAGE>
                                                               Exhibit " B"
                              ROYCE BIOMEDICAL INC.
                          Statement of Loss and Deficit
                        For the Year Ended June 30, 2002
                                  (US Dollars)


                                                           2002          2001


Other Income:
   Interest                                             $   5,000     $    973
-------------------------------------------------------------------------------
Expenses:
   Consulting fees                                          2,600       36,324
   Office and sundry                                       46,500        5,460
   Professional fees                                       21,600       37,955
   Rent                                                     3,900        4,540
   Stock transfer agents= fees                              1,600        4,465
Telephone                                                     900        1,436
   Travel and promotion                                       800       10,929
   Wages and benefits                                      32,600       34,803

                                                          110,500      135,912


Net Loss                                                  105,500      134,939
Deficit, beginning                                      2,497,200    2,362,295

-------------------------------------------------------------------------------

Deficit, ending, to Exhibit "A"                        $2,602,700   $2,497,234

Loss per share                                         $     0.02   $     0.01
-------------------------------------------------------------------------------



<PAGE>
                                                                  Exhibit "C"
                              ROYCE BIOMEDICAL INC.
                  Statement of Changes in Shareholders= Deficiency
                        For the Year Ended June 30, 2002
                                  (US Dollars)


                                         Common Shares     Capital   Accumulated
                                       Shares      Amount  Surplus     Deficit


Balance, June 30, 2000               3,364,138   $14,300  $2,322,000  $2,362,300
Shares issued for cash               1,500,000     1,500     298,500           -
Shares issued for debt                 187,545       200      37,300           -
Net Loss, per Exhibit "B"                    -         -           -     134,900

--------------------------------------------------------------------------------

Balance, June 30, 2001               5,051,683    16,000   2,657,800   2,497,200
Net Loss, per Exhibit "B"                    -         -           -     105,500

--------------------------------------------------------------------------------

Balance, June 30, 2002, to
 Exhibit "A"                         5,051,683   $16,000  $2,657,800  $2,602,700




<PAGE>


                                                             Exhibit "D"
                              ROYCE BIOMEDICAL INC.
                             Statement of Cash Flows
                        For the Year Ended June 30, 2002
                                  (US Dollars)


                                                            2002          2001


Operating Activities:
   Net Loss, per Exhibit "B"                             $(105,500)   $(134,939)

 Changes in non-cash working capital -
  (Increase) Decrease in accounts receivable                (1,100)      (6,695)
  (Increase) Decrease in prepaid expenses and deposits     100,500     (100,005)
   Increase (Decrease) in loan receivable - director        82,900      (82,894)
   Increase (Decrease) in accounts payable and accrued
    liabilities                                            (35,900)      (3,945)
   Increase (Decrease) in loan payable                           -      (50,000)


Cash flows from (used in) operating activities              40,900     (378,478)

Investing Activity:
   Increase in cost of licenses                           (100,000)           -

Financing Activity:
   Proceeds from issuance of common shares                       -      300,000

Net Decrease in Cash                                       (59,100)     (78,478)
Cash, beginning                                             59,200      137,655

--------------------------------------------------------------------------------

Cash, ending                                           $       100    $  59,177


Supplemental Disclosure of Cash Flow Information:
   Non-cash transaction (2001 only)
     187,545 common shares were issued in
     settlement of $37,508 debt to a related party




<PAGE>



                                                                 Exhibit "E"
                              ROYCE BIOMEDICAL INC.
                          Notes to Financial Statements
                                  June 30, 2002
                                  (US Dollars)


1.  Principles of Accounting and General Information:

    These financial statements have been prepared in accordance with accounting
    principles generally accepted in the United States.

    The Company was incorporated on March 22, 1995 under the jurisdiction of the
    State of Nevada.

2.  Accounting Policies:

    a)  Cash -

        Cash consists of bank accounts and short-term deposits integral to the
        Company's cash management.

    b)  Foreign Currency Translation -

    Assets and liabilities of Canadian operations are translated into United
    States currency at exchange rates prevailing at the balance sheet date for
    monetary items and at rates prevailing at the transaction date for
    non-monetary items. Revenue and expenses are converted at the average
    exchange rates for the year.

        Foreign exchange gains or losses on monetary assets and liabilities are
        included in operations.

    c)  Use of Estimates -

        The preparation of financial statements in conformity with generally
        accepted accounting principles requires management to make estimates and
        assumptions that affect the amounts reported in the financial statements
        and accompanying disclosures. Although these estimates are based on
        management's best knowledge of current events and actions the Company
        may undertake in the future, actual results may differ from the
        estimates.

3.  Financial Instruments:

    Fair Values -

    Unless otherwise noted, cash, accounts receivable, and accounts payable and
    accrued liabilities are stated at amounts that approximate their book value.

Product Licence Fees:
                                                        2002        2001

    Product license fees, at cost                   $110,000     $10,000
    Less:  Accumulated amortization                   10,000      10,000

                                                    $100,000     $     -



                                                                     . . . 2


<PAGE>


                                                                  Exhibit "E"
                                ROYCE BIOMEDICAL INC.             Continued
                          Notes to Financial Statements
                                  June 30, 2002
                                  (US Dollars)


4.    Product Licence Fees: (Continued)

    At June 30, 2002, the Company has applications in progress for license
    renewals of the H Pylori Antibody and M Tuberculosis Test Kits and has new
    applications in progress for HIV and Syphilis Test Kits in the People's
    Republic of China. During the year, the Company's agents have expended
    $100,000 towards the cost of these licenses.


5.  Share Capital and Contributed Surplus:

    Authorized -
        100,000,000 Common shares with a par value of $.001 each 5,000,000
            Preferred shares with a par value of $.001 each


                                                 Common Shares
               Contributed
    Issued and Outstanding -                 # Shares     Amount   Surplus
-------------------------------------------------------------------------------
Balance, June 30, 2002, no change            5,051,683   $16,000  $2,657,800
-------------------------------------------------------------------------------

    At June 30, 2002, 4,275,989 (2001 - 4,275,989) common shares were restricted
    from trading.

6.  Going Concern:

    While the financial statements have been prepared on the basis of accounting
    principles applicable to a going concern, the occurrence of significant
    losses to date raises substantial doubt upon the validity of this
    assumption.

    The Company has experienced significant losses over the past six years,
    including $105,500 in the current year and has an accumulated deficit of
    $2,602,700 at June 30, 2002. The Company's continued existence as a going
    concern is dependent upon its ability to continue to obtain adequate
    financing arrangements and to achieve and maintain profitable operations.

    If the going concern assumption was not appropriate for these financial
    statements, then adjustments may be necessary in the carrying value of
    assets and liabilities, the reported net loss and the balance sheet
    classifications used.

    The Company has financed its activities primarily from the proceeds of
    various share issues and loans from related companies. As a result of the
    Company being in the early stages of operations, the recoverability of
    assets on the balance sheet will be dependent on the Company's ability to
    obtain additional financing and to attain a level of profitable operations
    from the existing facilities in production and/or the disposition thereof.



                                                                    . . . 3


<PAGE>


                                                                  Exhibit "E"
                                ROYCE BIOMEDICAL INC.             Continued
                          Notes to Financial Statements
                                  June 30, 2002
                                  (US Dollars)


7.  Commitments:

    During the year ended June 30, 1997, the Company issued shares to a number
    of investors in British Columbia, Canada at $1.42 ($2.00 Canadian). Pursuant
    to the British Columbia Securities Act, an Offering Memorandum should have
    accompanied the issuance of these shares. As this did not occur, the
    shareholders were offered the opportunity to rescind the purchase of the
    shares for a refund of the entire purchase price. Requests from shareholders
    to rescind 14,250 common shares were received within the required time
    limit. The Company is required to refund an amount of $20,400. At June 30,
    2002, these amounts have not been repaid and are included in accounts
    payable and accrued liabilities.


8.  Related Party Transactions:

    In addition to the transactions described elsewhere in the financial
    statements, the Company had the following transactions with officers and
    directors of the Company.

                                                        2002        2001
                    -------------------------------------------------------
    Expenses -
        Consulting fees                            $       -     $20,000
        Wages                                         30,200      34,003

    Licence fees in progress                         100,000           -

    These transactions are in the normal course of operations and are measured
    at the exchange amount, which is the amount of consideration established and
    agreed to between the parties.


9.  Income Taxes:

    The Company has net losses for income tax purposes totaling approximately
    $2,592,900 which may be applied against future taxable income. The potential
    benefit arising from these losses has been recognized as a deferred tax
    asset. To the extent that those benefits may not be realized, a valuation
    allowance is provided for. The Company's deferred tax balances are as
    follows:

                                                        2002        2001
------------------------------------------------------------------------------
    Deferred tax asset, beginning                   $862,500    $819,265
    Benefit of current year's operating loss
    carried forward                                   34,700      43,235
------------------------------------------------------------------------------
    Deferred tax asset, ending                       897,200     862,500
------------------------------------------------------------------------------
    Valuation allowance, beginning                   862,500     819,265
    Current year's provision                          34,700      43,235
------------------------------------------------------------------------------
    Valuation allowance, ending                      897,200     862,500
------------------------------------------------------------------------------
                                                    $      -    $      -

                                                                     . . . 4


<PAGE>


                                                                Exhibit "E"
                                ROYCE BIOMEDICAL INC.           Continued
                          Notes to Financial Statements
                                  June 30, 2002
                                  (US Dollars)


9.  Income Taxes: (Continued)

    As the Company has no history of profits, management believes that it is
    more likely than not some or all of the deferred tax asset will not be
    realized and has provided a full valuation allowance against the deferred
    tax asset. The right to claim these losses expire as follows:

                    2010                         $173,000
                    2011                          599,000
                    2012                          748,000
                    2013                          509,000
                    2014                          163,900
                    2015                          159,600
                    2016                          134,900
                    2017                          105,500






<PAGE>


ITEM 13.  EXHIBITS AND REPORTS ON FORM 8-K

Exhibits

Exhibit
Number      Exhibit Name                                          Page Number

Exhibit 2   Plan of Acquisition, Reorganization, Arrangement,
            Liquidation, etc.                                        None

Exhibit 3   Articles of Incorporation, as amended, and Bylaws         (1)
                                                                  ----------

Exhibit 4   Instruments Defining the Rights of Security Holders

   Exhibit 4.1  Incentive Stock Option Plan                           (1)
                                                                  ----------

   Exhibit 4.2  Non-Qualified Stock Option Plan                       (1)
                                                                  ----------

   Exhibit 4.3  Stock Bonus Plan                                      (1)
                                                                  ----------

Exhibit 5Subscription Agreement                                      None

Exhibit 9Voting Trust Agreement                                      None

Exhibit 10Material Contracts                                         None

(1)  Incorporated by reference to the same exhibit filed with the Company's
     registration statement on Form 10-SB.



<PAGE>






                                   SIGNATURES


    In accordance with Section 13 or 15(a) of the Exchange Act, the Registrant
has caused this Report to be signed on its behalf by the undersigned, thereunto
duly authorized on the 27th day of September, 2002.

                                  ROYCE BIOMEDICAL, INC.

                                  By  /s/ Kathy Jiang
                                      ---------------------------------------
                                      Kathy Jiang, President and Principal
                                      Financial Officer

    Pursuant to the requirements of the Securities Act of l934, this Report has
been signed below by the following persons on behalf of the Registrant and in
the capacities and on the dates indicated.

                                     Title                    Date

/s/ Dr. Yan Xiao Wen
-----------------------------
Dr. Yan Xiao Wen                    Director             September 27, 2002

/s/ Kathy Jiang
-----------------------------
Kathy Jiang                         Director             September 27, 2002


                  REPORT OF CHIEF EXECUTIVE AND FINANCIAL OFFICER

      I, Kathy Jiang, as the Chief Executive and Financial Officer of the
Company, have evaluated the effectiveness of the Company's disclosure controls
and procedures as of a date within 90 days prior to the filing date of this
annual report (the "Evaluation Date"); and, in my opinion, the Company's
disclosure controls and procedures ensure that material information relating to
the Company, including its consolidated subsidiaries, is made known to me by
others within those entities, particularly during the period in which this
annual report is being prepared;

      To my knowledge there have been no significant changes in internal
controls or in other factors that could significantly affect internal controls
subsequent to the date of my most recent evaluation.

Date: September 27, 2002             /s/ Kathy Jiang
                                     -----------------------------------
                                     Kathy Jiang
                                     Chief Executive and Financial Officer



<PAGE>


                          CERTIFICATION PURSUANT TO THE
                               SARBANES-OXLEY ACT

I, Kathy Jiang, the Chief Executive and Financial Officer, certify that:

1.  I have reviewed this annual report on Form 10-KSB of Royce Biomedical, Inc.;

2. Based on my knowledge, this annual report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this annual
report;

3. Based on my knowledge, the financial statements, and other financial
information included in this annual report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this annual report;

4. I am responsible for establishing and maintaining disclosure controls and
procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the
registrant and have:

   a) designed such disclosure controls and procedures to ensure that material
      information relating to the registrant, including its consolidated
      subsidiaries, is made known to me by others within those entities,
      particularly during the period in which this annual report is being
      prepared;

   b) evaluated the effectiveness of the registrant's disclosure controls and
      procedures as of a date within 90 days prior to the filing date of this
      annual report (the "Evaluation Date"); and

   c) presented in this annual report   my   conclusions   about   the
      effectiveness  of  the  disclosure controls and procedures  based  on  my
      evaluation as of the Evaluation Date;

5. I have disclosed, based on my most recent evaluation, to the registrant's
auditors and the audit committee of registrant's board of directors (or persons
performing the equivalent functions):

   a) all significant deficiencies in the design or operation of internal
      controls which could adversely affect the registrant's ability to record,
      process, summarize and report financial data and have identified for the
      registrant's auditors any material weaknesses in internal controls; and

   b) any fraud,  whether or not material,  that involves management or other
      employees who have a significant  role  in  the   registrant's   internal
      controls; and

6. I have indicated in this annual report whether there were significant changes
in internal controls or in other factors that could significantly affect
internal controls subsequent to the date of my most recent evaluation, including
any corrective actions with regard to significant deficiencies and material
weaknesses.

Date: September 27, 2002             /s/ Kathy Jiang
                                     -----------------------------------
                                     _______________________
                                     Kathy Jiang
                                     Chief Executive and Financial Officer